Physician profile
Laura E Garrett
NPI 1104337369
$1,510.77
in general payments reported to CMS, 2019-2025
20 companies · $536 in 2025
The $536 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.66 · 2022: $129 · 2023: $334 · 2024: $463 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $293.40 | 2021-2025 | |
| Novo Nordisk INC | $178.58 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $152.33 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $128.63 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $104.63 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $91.23 | 2023-2024 | Rexulti |
| Lundbeck LLC | $88.44 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $86.66 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $64.70 | 2023 | Spravato |
| Collegium Pharmaceutical, INC. | $64.15 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $39.82 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $34.30 | 2024 | Trintellix |
| Amgen INC. | $33.90 | 2023-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $33.65 | 2021 | |
| Phathom Pharmaceuticals, INC. | $33.50 | 2024-2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.43 | 2023 | |
| Ironshore Pharmaceuticals INC. | $17.69 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.91 | 2025 | Caplyta |
| Astellas Pharma US INC | $16.15 | 2024 | Veozah |
| Harmony Biosciences LLC | $13.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.